Imaging software developer Median Technologies has signed on to provide image interpretation and management services for five new oncology clinical studies, valued at a total of 4.09 million euros.
A European biotech company and a pharmaceutical company have awarded three projects, including a phase III study in gastric cancer, a phase III study in cutaneous cancer, and a phase II study in melanoma, Median said. Other new contracts include a phase I/II study in liver cancer and a phase II study in primary central nervous system lymphoma.
